Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group

Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population

(2016) Qi Yang et al.   ANALYTICAL CHEMISTRY

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

(2016) I. M. van der Sluis et al.   HAEMATOLOGICA

Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation

(2016) I. M. van der Sluis et al.   HAEMATOLOGICA

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial

(2016) Joleen T. White et al.   Therapeutic Advances in Neurological Disorders

Acute Lymphoblastic Leukemia in Children

(2015) Stephen P. Hunger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activity and Toxicity of IntravenousErwiniaAsparaginase Following Allergy toE.coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia

(2015) Lynda M. Vrooman et al.   PEDIATRIC BLOOD & CANCER

Anti-PEG immunity: emergence, characteristics, and unaddressed questions

(2015) Qi Yang et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Anti-PEG antibody bioanalysis: a clinical case study with PEG-IFN-λ-1a and PEG-IFN-α2a in naive patients

(2015) Heather Myler et al.   Bioanalysis

A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

(2014) Wing H. Tong et al.   BLOOD

How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia

(2014) Michael J Burke   Future Oncology

Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial

(2014) Nicola Longo et al.   LANCET

Comparison of Allergic Reactions to Intravenous and Intramuscular Pegaspargase in Children with Acute Lymphoblastic Leukemia

(2014) William C. Petersen et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

(2014) Michael S Hershfield et al.   ARTHRITIS RESEARCH & THERAPY

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout

(2014) Peter E Lipsky et al.   ARTHRITIS RESEARCH & THERAPY

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group

(2013) W. L. Salzer et al.   BLOOD

Postinduction Dexamethasone and Individualized Dosing ofEscherichia ColiL-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01

(2013) Lynda M. Vrooman et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly

(2011) Mahati Pidaparti et al.   PEDIATRIC BLOOD & CANCER

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

(2009) L. B. Silverman et al.   BLOOD

The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations

(2009) Beata Zalewska-Szewczyk et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Is asparaginase a critical component in the treatment of acute lymphoblastic leukemia?

(2008) Dan Douer   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Biology and Treatment of Acute Lymphoblastic Leukemia

(2008) Rob Pieters et al.   PEDIATRIC CLINICS OF NORTH AMERICA